Article:In the View of Endothelial Microparticles: Novel Perspectives for Diagnostic and Pharmacological Management of Cardiovascular Risk during Diabetes Distress. (5971276)

From ScienceSource
Jump to: navigation, search

This page is the ScienceSource HTML version of the scholarly article described at https://www.wikidata.org/wiki/Q54972391. Its title is In the View of Endothelial Microparticles: Novel Perspectives for Diagnostic and Pharmacological Management of Cardiovascular Risk during Diabetes Distress. and the publication date was 2018-05-13. The initial author is Larissa Pernomian.

Fuller metadata can be found in the Wikidata link, which lists all authors, and may have detailed items for some or all of them. There is further information on the article in the footer below. This page is a reference version, and is protected against editing.



Converted JATS paper:

Journal Information

Title: Journal of Diabetes Research

In the View of Endothelial Microparticles: Novel Perspectives for Diagnostic and Pharmacological Management of Cardiovascular Risk during Diabetes Distress

  • Larissa Pernomian
  • Jôsimar Dornelas Moreira
  • Mayara Santos Gomes

1Department of Biosciences Applied to Pharmacy, Faculty of Pharmaceutical Sciences from Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil

2Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil

3Department of Physics and Chemistry, Faculty of Pharmaceutical Sciences from Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil

Publication date (collection): /2018

Publication date (epub): 5/2018

Abstract

Acute or chronic exposure to diabetes-related stressors triggers a specific psychological and behavior stress syndrome called diabetes distress, which underlies depressive symptoms in most diabetic patients. Distressed and/or depressive diabetic adults exhibit higher rates of cardiovascular mortality and morbidity, which have been correlated to macrovascular complications evoked by diabetic behavior stress. Recent experimental findings clearly point out that oxidative stress accounts for the vascular dysfunction initiated by the exposure to life stressors in diabetic conditions. Moreover, oxidative stress has been described as the main autocrine and paracrine mechanism of cardiovascular damage induced by endothelial microparticles (anuclear ectosomal microvesicles released from injured endothelial cells) in diabetic subjects. Such robust relationship between oxidative stress and cardiovascular diseases strongly suggests a critical role for endothelial microparticles as the primer messengers of the redox-dependent vascular dysfunction underlying diabetes distress. Here, we provide novel perspectives opened in the view of endothelial microparticles as promising diagnostic and pharmacotherapeutic biomarkers of cardiovascular risk in distressed diabetic patients.

Paper

1. Introduction

Diabetes distress has been described as a psychological and behavior stress syndrome of emotional symptoms that affect almost 50% of total diabetic patients [[1][7]]. Distressed diabetic patients exhibit higher rates of cardiovascular mortality and morbidity, which suggest a strong positive correlation between diabetes distress and cardiovascular risk of developing hypertension, dyslipidemia, atherosclerosis, myocardial infarction, stroke, and sudden death [[8][15]]. A few recent studies have shown that oxidative stress seems to be the key regulator of diabetes distress-induced cardiovascular diseases by impairing local anti-inflammatory nitrergic signaling [[3], [16][20]]. Beyond the redox-mediated cardiovascular dysfunction proposed in diabetes distress, submicron vesicles shed from activated or quiescent endothelial cells, called endothelial microparticles (EMPs), have been pointed out as the main mediators of cardiovascular dysfunction underlying isolated diabetes by inducing proinflammatory pathways. In brief, EMP generation is increased by the typical oxidative stress induced in diabetic subjects affected by diabetes-related cardiovascular complications [[21][25]]. Taken together, these findings suggest that EMPs could represent a putative link between diabetes distress and the underlying redox-mediated cardiovascular dysfunction. Since there are no reports regarding the potential role assigned to EMPs as the downstream mediators of diabetes distress-related cardiovascular diseases, here we provide hypothetical mechanistic insights thereon by opening novel perspectives for the forthcoming use of EMPs as a diagnostic tool and pharmacological target for managing cardiovascular risk in distressed diabetic patients.

2. Diabetes Distress: Can Stress Hurt?

Considering that this question is not as simple as it seems to be, the more appropriate answer would be: it depends on how long stress lasts and how regulated the stress-based reactions are. If we understand psychological stress as an adaptive behavior resultant from transient neurological and hormonal responses induced for the sole purpose of ensuring survival [[26]], we would conclude that stress protects instead of hurts. However, if stress lasts for a long enough time and/or its reactions run on unregulated pathways, it can certainly hurt by triggering or contributing to the advance of a pathological environment [[27]]. In both cases, the outcomes of psychological stress arise from the hyperactivation of the hypothalamic-pituitary axis (HPA), whose tissue and systemic effects comprise extensive transcriptional and epigenetic changes [[28]].

In the view of diabetes, there are innumerous disease-related stressors that acutely or chronically activate HPA in an unregulated fashion, which leads to irregular peaks of serum corticosterone [[29]]. Overall, diabetes-related stressors comprise the following: significant emotional reactions to the diagnosis; requirement of self-management; blame and denial in dealing with the disease, the oppressive self-management, and the social restrictions surrounding diabetic conditions; threats of diabetic complications; general diabetic depletion; and potential loss of function [[1][3]]. The irregular corticosterone peaks induced by diabetes-related stressors feedback their own behavior effects [[30]], leading to an expected stress reaction called diabetes distress, which rises as an affective experience involving wide emotional responses such as fears, worries, concerns, blame, and burden [[2][7]]. In addition to the behavior effects, the irregular corticosterone peaks induced by diabetes-related stressors also enhance diabetic insulin resistance and hyperglycemia, which contribute to the progression of diabetes [[30]]. For these reasons, diabetes distress is also correlated to a suboptimal glycemic control [[4], [31], [32]].

Diabetes distress is a very common condition so that up to 45% of type 2-diabetic patients experience its emotional symptoms [[1][3]]. This high incidence reduces the complacence of distressed diabetic patients for pharmacotherapy, diet, or physical exercises in 5–15%, 30%, or 80%, respectively [[33]]. For these reasons, these subjects exhibit higher rates of mortality correlated to all causes [[34]].

Although diabetes distress is a specific psychological and behavior stress syndrome that belongs to the diabetes spectrum, it has been described as a nonspecific indicator of clinical psychiatric comorbidities since it underlies major depression, elevated depressive symptoms, and subclinical depression that are widely developed by diabetic patients [[2][7]]. About 20–30% of distressed diabetic patients experience clinical depressive symptoms [[4], [35]] so that the prevalence of major depression is two- or three-fold higher in type 2- or type 1-diabetic patients than in the general population, respectively [[3], [36]]. Both diabetes distress and major depression prognosis worsen when the two conditions coexist [[37]]: while HPA hyperactivity in distressed diabetic patients contributes to the progression of clinical depression, sympathomedular activation in depressive patients contributes to the insulin resistance during diabetes progression [[38]]. Taken together, these considerations support the importance of appropriately treating distressed diabetic patients in an attempt to avoid stress hurting. For these purposes, an effective glycemic control associated to behavior-cognitive approaches for improving diabetic prognosis and controlling the emotional stress and the eventual coexistent psychiatric symptoms has been considered one of the most effective choices [[39]].

3. Diabetes Distress and Cardiovascular Risk: What Is in Common?

There is much in common between diabetes distress and cardiovascular risk, starting with their prevalence as comorbidities. It is well documented that cardiovascular diseases represent the major cause of morbidity and mortality among diabetic patients, who exhibit a two-fold higher cardiovascular risk than the normoglycemic population [[16], [40]]. However, this higher incidence does not depend only on the traditional risk factors for cardiovascular diseases but it is strongly correlated to the behavior risk factors [[40]], pointing at diabetes distress as the major cause of cardiovascular complications underlying chronic hyperglycemia in stressed diabetic subjects [[8]].

Accordingly, distressed diabetic patients have a 1.69-fold higher risk for developing cardiovascular events [[9]], a 1.8-fold higher risk for developing cardiac ischemic diseases [[10]], and a 1.76-fold higher risk of cardiovascular mortality [[9]]. When diabetes distress is followed by clinical psychiatric disorders, cardiovascular risk gets a substantial increase of 39% [[11]] so that distressed depressive diabetic patients have a 2.4- to 3.5-fold higher risk of cardiovascular mortality [[12]]. Hypertension and macrovascular complications (myocardial infarction, stroke, and sudden death) are the most expressive cardiovascular events expressed in these patients, counting on a risk of 56% [[13]] and 24–82% [[14], [15]], respectively.

A marked positive correlation between diabetes distress and the main biomarkers of cardiovascular diseases (i.e., glycosylated hemoglobin (HbA1c), diastolic pressure, and low-density lipoprotein-cholesterol (LDL-c)) was recently confirmed in the most common cardiovascular events expressed in these patients [[3], [16]]. Accordingly, several studies have attempted to elucidate the mechanisms underlying the increased cardiovascular risk in diabetes distress. In this sense, recent studies have confirmed the critical role played by oxidative stress in exacerbating vascular diseases during experimental diabetes distress, which is induced by the behavior restraint stress model. Moreira et al. [[17], [18]] have showed that the contractile carotid hyperreactivity underlying cerebrovascular complication in stressed diabetic animals involves the upregulation of NADPH/Nox4 oxidase-driven generation of hydrogen peroxide (H2O2) [[17]] and inducible nitric oxide synthase (iNOS)-driven generation of peroxynitrite (ONOO−) [[18]]. The authors have demonstrated that the increased generation of H2O2 and ONOO− is induced by the acute exposure of rats to restraint stress, which increases carotid resistance by enhancing the local preexistent diabetes-related angiotensinergic hyperreactivity [[19]] due to the contractile effects evoked by the referred reactive oxygen species (ROS) [[17], [18]]. In agreement with these findings, Matsuura et al. [[20]] showed that the chronic exposure of animals with metabolic syndrome (DahlS.Z-Leprfa/Leprfa/obese rats) to restraint stress exacerbates the preexisting hypertension, ventricular hypertrophy fibrosis, and diastolic dysfunction by cardiovascular oxidative stress- and proinflammatory-dependent mechanisms and hyperactivation of the local renin-angiotensin system (RAS). The clinical and experimental findings regarding the biomarkers of diabetes distress-related cardiovascular risk are summarized in Table 1.

The experimental correlations assigned to renin-angiotensin system (RAS) activation and redox signaling suggest vascular dysfunction as the putative key mechanism underlying the increased cardiovascular risk during diabetes distress [[3], [16], [17], [20]]. Indeed, angiotensinergic oxidative stress has been described as a critical mechanism for inducing general vascular dysfunction under both stressful [[41][44]] and hyperglycemic [[19]] stimuli. In turn, vascular dysfunction underlies all of the diabetic cardiovascular complications during their early preclinical stages [[45]]. Thus, the identification of integrative molecular players of redox-dependent vascular dysfunction provides a novel pathophysiological understanding of cardiovascular risk in diabetes distress and novel insights for selectively targeting vascular competence for diagnosis, prognosis, and therapy purposes.

4. Cardiovascular Risk in Diabetes Distress and Endothelial Microparticles: Could They Be Linked?

When taking oxidative stress into account, cardiovascular risk in diabetes distress can certainly be linked to endothelial microparticles (EMPs), which have been described as noninvasive surrogate biomarkers of redox-induced vascular injury and dysfunction correlated with poor clinical outcomes in cardiovascular diseases [[45]]. In brief, EMPs are submicron vesicles ranging from 0.1 to 1.0 μm in diameter, shed from the blebbing of plasma membrane of activated or quiescent endothelial cells during prooxidant events that lead to a direct effect of ROS on the vasculature such as shear stress-induced blood pressure disorders (which induces ROS generation upon NADPH oxidase activation), the agonist activation of receptors attached to redox signaling (such as angiotensin AT1, endothelin ETA, endothelin ETB, and TNFα-I receptors), the redox-induced cell apoptosis, and/or the oxidative stress-mediated mitochondrial dysfunction [[21], [46][48]]. As autocrine and paracrine mediators, EMPs elicit oxidative stress in endothelial cells by increasing the local ROS generation and triggering underlying redox-proinflammatory mechanisms that (1) downregulate nitric oxide (NO) release by inducing the uncoupling of endothelial nitric oxide synthase (eNOS) and (2) disrupt the endothelium competence on nitrergic anti-inflammatory signaling [[49]]. This effect may be due to the expression of functionally active NADPH oxidase subunits (p22phox, p38phox, p47phox, p67phox, Nox1, Nox2, and Nox4) in EMPs [[50]].

Circulating EMPs represent the minority of total microparticles in healthy conditions but their levels are substantially increased by the oxidative stress-induced lipid peroxidation in endothelial cells during diabetes or cardiovascular diseases [[21][25]]. Moreover, diabetic cardiovascular complications increase the circulating levels of EMPs when compared to isolated diabetes or cardiovascular diseases [[51], [52]]. Interestingly, diabetes seems to increase EMPs' competence in inducing vascular dysfunction. Jansen et al. [[53]] recently showed that the redox-dependent vascular inflammation in atherosclerotic lesions (i.e., macrophage infiltration and adhesion protein expression) is higher when induced by EMPs derived from endothelial cells exposed to diabetes-like hyperglycemic conditions. Accordingly, although high glucose levels did not change EMPs' morphology (i.e., size and antigen composition), the hyperglycemia increases the functionality of EMPs in activating NADPH oxidase/p38phox-mediated signaling when compared to EMPs formed in a normoglycemic environment [[53]]. The clinical significance of such redox/proinflammatory potential assigned to diabetic EMPs lies in their prognostic value for coronary artery disease in diabetes due to the positive correlation between the high circulating EMP levels and the severity of vascular dysfunction in diabetic patients [[23], [54], [55]]. Taken together with the well-described remarkable increase in vascular inflammation, vascular ROS generation, and vascular NAPH oxidase complex expression and functionality in animal models of diabetes distress [[17][20]], the stronger competence of diabetic EMPs in inducing oxidative vascular injury and dysfunction points at EMPs as feasible integrative molecular players of the increased cardiovascular risk in diabetes distress [[8][16], [40]]. Such hypothetical mechanistic insights are summarized in Figure 1. Therefore, selectively targeting EMPs may represent a promising perspective for effective diagnostic, prognostic, and therapeutic purposes aimed at the cardiovascular risk in distressed diabetic patients.

5. In the view of Endothelial Microparticles: Novel Insights for Cardiovascular Risk Management in Diabetes Distress!

The recent findings described here concerning the oxidative potential assigned to EMPs in inducing diabetic cardiovascular complications open real perspectives for managing cardiovascular risk during diabetes distress by considering EMPs as diagnostic key hallmarks and pharmacological targets. For diagnostic purposes, the circulating levels of EMPs can be quantified by polychromatic flow cytometry as the simplest method that provides valuable information regarding the antigen composition and size criteria [[56], [57]]. In these cases, platelet-poor plasma must be obtained by serial centrifugation or ultracentrifugation of freshly drawn whole blood samples, since freezing or storage approaches disrupt the microparticles' integrity. Also, the blood samples must be pretreated with calcium (Ca2+)-chelator anticoagulants (e.g., EDTA or sodium citrate) for avoiding microparticle aggregation. Once prepared, the platelet-poor plasma is labeled with fluorescent monoclonal antibodies for staining specific surface antigens expressed on endothelial cells such as CD31 and CD54, and the cytometric analysis is performed by applying forward and side light scatter with calibration beads of a known diameter [[58]].

A few recent studies have shown that some specific pharmacological interventions are able to promote protective effects by significantly reducing circulating levels of EMPs in diabetic patients affected by cardiovascular diseases including hypertension. For instance, the Ca2+ blockers nifedipine and benifipine, combined or not with the angiotensin AT1 antagonist losartan, were able to reduce EMP formation in hypertensive diabetic patients by antioxidant mechanisms that inhibited lipid peroxidation in endothelial cells rather than hypotensive effects [[59][61]]. Similarly, statins such as simvastatin and fluvastatin, as well as vitamin C and losartan, reduced the circulating levels of EMPs in hypertensive hyperlipidemic diabetic patients affected by advanced atherosclerotic plaques [[22], [60], [62][64]]. Interestingly, the therapeutic effects of these drugs on EMP circulating levels result from pharmacological actions that interfere with the mechanisms of EMP formation. Indeed, it would not be feasible to selectively target EMPs with specific antibodies or scavengers since other microparticles stemmed from different parental cells share some of the surface antigens expressed by EMPs including CD31 and CD54 [[65]]. Currently, these mechanisms are summarized as the shedding of activated or quiescent endothelial cell plasma membrane blebbing, which can result from the increase of intracellular Ca2+ or ROS levels induced by shear stress, agonist receptor activation (including the activation of angiotensin AT1, endothelin ETA, endothelin ETB, and TNFα-I receptors), apoptosis, or oxidative stress-mediated mitochondrial dysfunction [[21], [46][48], [66][68]]. However, recent studies have shown that lipid-lowering therapies inhibit EMP formation by an unknown mechanism [[69], [70]] that putatively interferes with the Rho-kinase pathway [[63]]. Such information highlights the importance of accurately identifying all the pathophysiological mechanisms of EMP formation so that they can be defined as pharmacological targets for controlling cardiovascular risk in distressed diabetic patients.

Although there are no reports concerning the direct effects of selective serotonin reuptake inhibitors (IRS) on circulating EMP levels from depressive distressed diabetic patients [[71]], experimental findings have shown that escitalopram and paroxetine prevent vascular dysfunction in chronically stressed or diabetic rats by cardiac and endothelial antioxidant mechanisms [[72][74]]. Taken together, these findings suggest a novel therapeutic role for IRS as protective agents on the cardiovascular system by putatively inhibiting the redox-dependent formation of EMPs during stressful and/or diabetic conditions. The confirmation of this hypothesis would then make IRS an important pharmacological tool as reliable as Ca2+ blockers, statins, AT1 antagonists, or antioxidants for managing cardiovascular risk in diabetes distress.

Acknowledgements

Acknowledgments

The authors thank Professor Cristina Ribeiro de Barros Cardoso for her scientific support. This work was supported by the Coordination for the Improvement of Higher Education Personnel (CAPES), by the National Postdoctorate Program of CAPES (PNPD/CAPES), and by the São Paulo Research Foundation (FAPESP, Brazil, Grant nos. 2014/17740-0, 2013/08216-2, 2012/00640-7, 2012/09019-3, and 2009/01005-0).

References

  1. L. FisherJ. C. N. ChanH. NanN. SartoriusB. OldenburgCo-occurrence of diabetes and depression: conceptual considerations for an emerging global health challenge2012142S56S6610.1016/s0165-0327(12)70009-52-s2.0-8486739415023062858
  2. L. FisherJ. S. GonzalezW. H. PolonskyThe confusing tale of depression and distress in patients with diabetes: a call for greater clarity and precision201431776477210.1111/dme.124282-s2.0-8490247340724606397
  3. K. E. KreiderDiabetes distress or major depressive disorder? A practical approach to diagnosing and treating psychological comorbidities of diabetes2017811710.1007/s13300-017-0231-12-s2.0-8501220660728160185
  4. L. FisherJ. T. MullanP. AreanR. E. GlasgowD. HesslerU. MasharaniDiabetes distress but not clinical depression or depressive symptoms is associated with glycemic control in both cross-sectional and longitudinal analyses2010331232810.2337/dc09-12382-s2.0-7424909823819837786
  5. J. S. GonzalezL. FisherW. H. PolonskyDepression in diabetes: have we been missing something important?201134123623910.2337/dc10-19702-s2.0-7995168474721193621
  6. S. A. EsbittM. L. TanenbaumJ. S. GonzalezC. E. LloydF. PouwerN. HermansDisentangling clinical depression from diabetes-specific distress: making sense of the mess we’ve made2013LondonSpringer10.1007/978-0-85729-751-8_2
  7. L. GaskW. MacdonaldP. BowerWhat is the relationship between diabetes and depression? A qualitative meta-synthesis of patient experience of co-morbidity20117323925210.1177/17423953114036362-s2.0-8005263297021840916
  8. K. SemenkovichM. E. BrownD. M. SvrakicP. J. LustmanDepression in type 2 diabetes mellitus: prevalence, impact, and treatment201575657758710.1007/s40265-015-0347-42-s2.0-8493776541525851098
  9. E.-M. DalsgaardM. VestergaardM. V. SkriverPsychological distress, cardiovascular complications and mortality among people with screen-detected type 2 diabetes: follow-up of the ADDITION-Denmark trial201457471071710.1007/s00125-014-3165-42-s2.0-8489610185224442448
  10. M. C. AdriaanseF. PouwerJ. M. DekkerDiabetes-related symptom distress in association with glucose metabolism and comorbidity200831122268227010.2337/dc08-10742-s2.0-6434911273718728236
  11. R. J. AndersonA. B. GrigsbyK. E. FreedlandAnxiety and poor glycemic control: a meta-analytic review of the literature200232323524710.2190/KLGD-4H8D-4RYL-TWQ82-s2.0-0036983207
  12. L. EgedeP. J. NietertD. ZhengDepression and all-cause and coronary heart disease mortality among adults with and without diabetes20052861339134510.2337/diacare.28.6.13392-s2.0-1994441149515920049
  13. A. K. KhuwajaS. LalaniR. DhananiI. S. AzamG. RafiqueF. WhiteAnxiety and depression among outpatients with type 2 diabetes: a multi-centre study of prevalence and associated factors201021727710.1186/1758-5996-2-722-s2.0-7865026472621171976
  14. E. H. B. LinC. M. RutterW. KatonDepression and advanced complications of diabetes: a prospective cohort study201033226426910.2337/dc09-10682-s2.0-7514918284019933989
  15. J. F. ScherrerL. D. GarfieldT. ChruscielIncreased risk of myocardial infarction in depressed patients with type 2 diabetes20113481729173410.2337/dc11-00312-s2.0-8485598351821680721
  16. R. J. WinchesterJ. S. WilliamsT. E. WolfmanL. E. EgedeDepressive symptoms, serious psychological distress, diabetes distress and cardiovascular risk factor control in patients with type 2 diabetes201630231231710.1016/j.jdiacomp.2015.11.0102-s2.0-8494966650926657725
  17. J. D. MoreiraL. PernomianM. S. GomesAcute restraint stress increases carotid reactivity in type-I diabetic rats by enhancing Nox4/NADPH oxidase functionality201576550351610.1016/j.ejphar.2015.09.0202-s2.0-8494322532226387612
  18. J. D. MoreiraL. PernomianM. S. GomesEnhanced nitric oxide generation from nitric oxide synthases as the cause of increased peroxynitrite formation during acute restraint stress: effects on carotid responsiveness to angiotensinergic stimuli in type-1 diabetic rats2016783112210.1016/j.ejphar.2016.04.0502-s2.0-8496461716727118175
  19. L. PernomianM. S. GomesC. B. A. RestiniL. N. Z. RamalhoC. R. TirapelliA. M. de OliveiraThe role of reactive oxygen species in the modulation of the contraction induced by angiotensin II in carotid artery from diabetic rat20126781–3152510.1016/j.ejphar.2011.12.0362-s2.0-8485703876922227335
  20. N. MatsuuraK. NagasawaY. MinagawaRestraint stress exacerbates cardiac and adipose tissue pathology via β-adrenergic signaling in rats with metabolic syndrome201530810H1275H128610.1152/ajpheart.00906.20142-s2.0-8493083481825770247
  21. A. S. LeroyerA. TedguiC. M. BoulangerMicroparticles and type 2 diabetes200834273210.1016/s1262-3636(08)70100-92-s2.0-40749110620
  22. O. MorelL. JeselB. HugelProtective effects of vitamin C on endothelium damage and platelet activation during myocardial infarction in patients with sustained generation of circulating microparticles20031117117710.1046/j.1538-7836.2003.00010.x2-s2.0-014148435912871555
  23. H. KogaS. SugiyamaK. KugiyamaElevated levels of VE-cadherin-positive endothelial microparticles in patients with type 2 diabetes mellitus and coronary artery disease200545101622163010.1016/j.jacc.2005.02.0472-s2.0-2104443817615893178
  24. F. SabatierP. DarmonB. HugelType 1 and type 2 diabetic patients display different patterns of cellular microparticles20025192840284510.2337/diabetes.51.9.28402-s2.0-003672472212196479
  25. B. FengY. ChenY. LuoM. ChenX. LiY. NiCirculating level of microparticles and their correlation with arterial elasticity and endothelium-dependent dilation in patients with type 2 diabetes mellitus2010208126426910.1016/j.atherosclerosis.2009.06.0372-s2.0-7344910468219674745
  26. A. S. ZannasG. P. ChrousosEpigenetic programming by stress and glucocorticoids along the human lifespan201722564064610.1038/mp.2017.352-s2.0-8501504812828289275
  27. S. CohenP. J. GianarosS. B. ManuckA stage model of stress and disease201611445646310.1177/17456916166463052-s2.0-8498001887227474134
  28. M. van BodegomJ. R. HombergM. J. A. G. HenckensModulation of the hypothalamic-pituitary-adrenal axis by early life stress exposure201711p. 8710.3389/fncel.2017.000872-s2.0-85018259258
  29. E. M. KyritsiG. KoltsidaI. FaraklaPsychological vulnerability to stress in carriers of congenital adrenal hyperplasia due to 21-hydroxylase deficiency2017161425310.14310/horm.2002.17182-s2.0-8501941454128500827
  30. J. D. ShenY. WeiY. J. LiJ. Y. QiaoY. C. LiCurcumin reverses the depressive-like behavior and insulin resistance induced by chronic mild stress20173241163117210.1007/s11011-017-0017-12-s2.0-8501768305028429187
  31. L. FisherR. E. GlasgowL. A. StryckerThe relationship between diabetes distress and clinical depression with glycemic control among patients with type 2 diabetes20103351034103610.2337/dc09-21752-s2.0-7795490271720150291
  32. L. FisherM. M. SkaffJ. T. MullanClinical depression versus distress among patients with type 2 diabetes: not just a question of semantics200730354254810.2337/dc06-16142-s2.0-3384768903417327318
  33. H. RoohafzaA. KabirM. SadeghiStress as a risk factor for noncompliance with treatment regimens in patients with diabetes and hypertension201612416617128149311
  34. F. E. van DoorenG. NefsM. T. SchramF. R. J. VerheyJ. DenolletF. PouwerDepression and risk of mortality in people with diabetes mellitus: a systematic review and meta-analysis201383, article e5705810.1371/journal.pone.00570582-s2.0-8487462644323472075
  35. M. L. TanebaumJ. S. GonzalezThe influence of diabetes on a clinician-rated assessment of depression in adults with type 1 diabetes201238569570410.1177/01457217124527952-s2.0-84871704217
  36. T. RoyC. E. LloydEpidemiology of depression and diabetes: a systematic review2012142S8S2110.1016/S0165-0327(12)70004-62-s2.0-8486733841823062861
  37. C. E. LloydG. PambiancoT. J. OrchardDoes diabetes-related distress explain the presence of depressive symptoms and/or poor self-care in individuals with type 1 diabetes?201027223423710.1111/j.1464-5491.2009.02896.x2-s2.0-7624913204020546270
  38. J. K. RustadD. L. MusselmanC. B. NemeroffThe relationship of depression and diabetes: pathophysiological and treatment implications20113691276128610.1016/j.psyneuen.2011.03.0052-s2.0-8005270337021474250
  39. S. A. SafrenJ. S. GonzalezD. J. WexlerA randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in patients with uncontrolled type 2 diabetes201437362563310.2337/dc13-08162-s2.0-8489670827024170758
  40. R. A. HackettA. SteptoePsychosocial factors in diabetes and cardiovascular risk20161810p. 9510.1007/s11886-016-0771-42-s2.0-8498374754227566328
  41. I. M. ChungY. M. KimM. H. YooM. K. ShinC. K. KimS. H. SuhImmobilization stress induces endothelial dysfunction by oxidative stress via the activation of the angiotensin II/its type I receptor pathway2010213110911410.1016/j.atherosclerosis.2010.08.0522-s2.0-7795845617320850747
  42. M. GroeschelB. BraamConnecting chronic and recurrent stress to vascular dysfunction: no relaxed role for the renin-angiotensin system20113001F1F1010.1152/ajprenal.00208.20102-s2.0-7865128319720980410
  43. W. Costa-FerreiraJ. O. VieiraJ. AlmeidaL. Gomes-de-SouzaC. C. CrestaniInvolvement of type 1 angiontensin II receptor (AT1) in cardiovascular changes induced by chronic emotional stress: comparison between homotypic and heterotypic stressors20167p. 26210.3389/fphar.2016.002622-s2.0-84988691115
  44. H. CôcoL. PernomianP. C. PereiraChronic restraint stress increases angiotensin II potency in the rat carotid: role of cyclooxygenases and reactive oxygen species2017691526510.1111/jphp.126592-s2.0-8499652377027774650
  45. F. SabatierL. Camoin-JauF. AnfossoJ. SampolF. Dignat-GeorgeCirculating endothelial cells, microparticles and progenitors: key players towards the definition of vascular competence200913345447110.1111/j.1582-4934.2008.00639.x2-s2.0-6304909755019379144
  46. F. SantilliM. MarchisioP. LanutiA. BoccatondaS. MisciaG. DavìMicroparticles as new markers of cardiovascular risk in diabetes and beyond2016116222023410.1160/TH16-03-01762-s2.0-84980369533
  47. P. PudduG. M. PudduE. CraveroS. MuscariA. MuscariThe involvement of circulating microparticles in inflammation, coagulation and cardiovascular diseases201026e140e14510.1016/s0828-282x(10)70371-8
  48. S. ChanQ. LianM. P. ChenDeferiprone inhibits iron overload-induced tissue factor bearing endothelial microparticle generation by inhibition oxidative stress induced mitochondrial injury, and apoptosis201833814815810.1016/j.taap.2017.11.0052-s2.0-8503707688429132816
  49. M. E. TushuizenR. NieuwlandC. RustemeijerElevated endothelial microparticles following consecutive meals are associated with vascular endothelial dysfunction in type 2 diabetes200730372873010.2337/dc06-14732-s2.0-3384761030217327351
  50. D. BurgerM. TurnerM. N. MunkondaR. M. TouyzEndothelial microparticle-derived reactive oxygen species: role in endothelial signaling and vascular function2016201610504795410.1155/2016/50479542-s2.0-84975166499
  51. A. S. LeroyerH. IsobeG. LesècheCellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques200749777277710.1016/j.jacc.2006.10.0532-s2.0-3384689524717306706
  52. K. EspositoM. CiotolaF. GiuglianoEndothelial microparticles correlate with erectile dysfunction in diabetic men200719216116610.1038/sj.ijir.39015002-s2.0-3384739830416900206
  53. F. JansenX. YangB. S. FranklinHigh glucose condition increases NADPH oxidase activity in endothelial microparticles that promote vascular inflammation20139819410610.1093/cvr/cvt0132-s2.0-8487516127923341580
  54. N. AmabileA. P. GuérinA. LeroyerCirculating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure200516113381338810.1681/ASN.20050505352-s2.0-3364487617416192427
  55. N. WernerS. WassmannP. AhlersS. KosiolG. NickenigCirculating CD31+/annexin V+ apoptotic microparticles correlate with coronary endothelial function in patients with coronary artery disease200626111211610.1161/01.ATV.0000191634.13057.152-s2.0-33644831131
  56. F. DengS. WangL. ZhangEndothelial microparticles act as novel diagnostic and therapeutic biomarkers of diabetes and its complications: a literature review201620168980202610.1155/2016/98020262-s2.0-84994360764
  57. P. LanutiF. SantilliM. MarchisioA novel flow cytometric approach to distinguish circulating endothelial cells from endothelial microparticles: relevance for the evaluation of endothelial dysfunction20123801-2162210.1016/j.jim.2012.03.0072-s2.0-84861187376
  58. S. NomuraMicroparticle and atherothrombotic diseases20162311910.5551/jat.323262-s2.0-8495337645126412494
  59. S. NomuraN. InamiY. KimuraEffect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus2007211384410.1038/sj.jhh.10021002-s2.0-3384554433517051237
  60. S. NomuraA. ShouzuS. OmotoM. NishikawaS. FukuharaT. IwasakaLosartan and simvastatin inhibit platelet activation in hypertensive patients200418317718510.1007/s11239-005-0343-82-s2.0-1754437570715815879
  61. S. NomuraA. ShouzuS. OmotoM. NishikawaT. IwasakaBenidipine improves oxidized LDL-dependent monocyte and endothelial dysfunction in hypertensive patients with type 2 diabetes mellitus200519755155710.1038/sj.jhh.10018632-s2.0-2174445690615829999
  62. S. NomuraA. ShouzuS. OmotoEffects of eicosapentaenoic acid on endothelial cell-derived microparticles, angiopoietins and adiponectin in patients with type 2 diabetes2009162839010.5551/jat.E0912-s2.0-6754913639519403992
  63. A. F. TramontanoJ. O’LearyA. D. BlackR. MuniyappaM. V. CutaiaN. el-SherifStatin decreases endothelial microparticle release from human coronary artery endothelial cells: implication for the Rho-kinase pathway20043201343810.1016/j.bbrc.2004.05.1272-s2.0-294268263515207698
  64. O. MorelF. TotiB. HugelProcoagulant microparticles: disrupting the vascular homeostasis equation?200626122594260410.1161/01.ATV.0000246775.14471.262-s2.0-33751169794
  65. C. N. FrançaM. C. IzarJ. B. AmaralD. M. TeganiF. A. FonsecaMicroparticles as potential biomarkers of cardiovascular disease2015104216917410.5935/abc.201402102-s2.0-8492637026925626759
  66. S. YangQ. ZhongZ. QiuAngiotensin II receptor type 1 autoantibodies promote endothelial microparticles formation through activating p38 MAPK pathway201432476277010.1097/HJH.00000000000000832-s2.0-8489627681524609215
  67. M. LichtenayerB. GoebelV. PaarAcute effects of moderate altitude on biomarkers of cardiovascular inflammation and endothelial function and their differential modulation by dual endothelin receptor blockade201767110111310.3233/CH-1702732-s2.0-8503167107528550241
  68. S. K. LeeS. H. YangI. KwonO. H. LeeJ. H. HeoRole of tumour necrosis factor receptor-1 and nuclear factor-κB in production of TNF-α-induced pro-inflammatory microparticles in endothelial cells2014112258058810.1160/TH13-11-09752-s2.0-84929963454
  69. R. SuadesT. PadróR. AlonsoP. MataL. BadimonLipid-lowering therapy with statins reduces microparticle shedding from endothelium, platelets and inflammatory cells2013110236637710.1160/TH13-03-02382-s2.0-84880784725
  70. F. MobarrezN. EgbergJ. AntovicA. BröijersenG. JörneskogH. WallénRelease of endothelial microparticles in vivo during atorvastatin treatment; a randomized double-blind placebo-controlled study20121291959710.1016/j.thromres.2011.09.0272-s2.0-8465516500222035651
  71. S. RoopanE. R. LarsenUse of antidepressants in patients with depression and comorbid diabetes mellitus: a systematic review201729312713910.1017/neu.2016.542-s2.0-84992313119
  72. V. V. MatchkovV. V. KravtsovaO. WiborgC. AalkjaerE. V. BouzinovaChronic selective serotonin reuptake inhibition modulates endothelial dysfunction and oxidative state in rat chronic mild stress model of depression20153098R814R82310.1152/ajpregu.00337.20142-s2.0-84944402405
  73. D. GeröP. SzoleczkyK. SuzukiCell-based screening identifies paroxetine as an inhibitor of diabetic endothelial dysfunction201362395396410.2337/db12-07892-s2.0-8487444523623223176
  74. S. B. WheatcroftTeaching an old drug new tricks: can paroxetine ease the burden of cardiovascular disease in diabetes?201362369870010.2337/db12-15302-s2.0-8487441920423431014
The underlying source XML for this text is taken from https://www.ebi.ac.uk/europepmc/webservices/rest/PMC5971276/fullTextXML. The license for the article is Creative Commons Attribution 4.0 International. The main subject has been identified as complications of diabetes mellitus.